An observational study in Colorectal Neoplasms, sponsored by University Hospital, Bordeaux. Not yet recruiting at 14 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by University Hospital, Bordeaux · Observational
Colorectal cancer is a common and leading cause of death. Pre-cancerous lesions, as well as some so-called superficial cancers, can be resected via endoscopy. The technique chosen in the case of extensive lesions or superficial cancer is submucosal dissection. This technique helps avoid surgery, which has a higher morbidity and mortality (especially due to the non-preservation of the organ).
French data from over 4,000 dissections (French Colorectal ESD Cohort in Experts Centers, FECCo, Clinical Trial NCT04592003) of LST (Lateral Spreading Tumor) or superficial colorectal cancer show reassuring results in terms of effectiveness with an 88% complete resection rate (R0) and safety with 1.2% of secondary surgery due to complications. Due to the absence of lymph node dissection compared to surgery, there is a theoretical risk of higher lymphatic recurrence with submucosal dissection. This study would allow for a better preoperative assessment of the benefit/risk ratio, as well as a more tailored therapeutic approach afterward based on the course of the resection and the analysis of the surgical specimen.
5,734 studies on the registry are indexed under Colorectal Neoplasms; 1,481 are open to participants now.
This study's planned enrollment of 1,200 is above the median of 250 across 1,253 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →University Hospital, Bordeaux is the lead sponsor of 803 studies on the registry; 194 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will be drawn from the FECCo registry and will include patients who have undergone endoscopic resection using ESD, with final histological analysis confirming the presence of a colorectal cancer at high risk of lymph node recurrence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who underwent surgery, radiochimiotherapy or nothing.
Procedure: Surgery, Radiochimiotherapy
Analysis of medical data and residual biological samples
Recurrence-free survival
Proportion of patients who remain free of oncological recurrence, either locoregional and/or metastatic, at 12 months after ESD.
Time frame: 12 months visit
Post-adjuvant treatment mortality
Proportion of patients who have died from any cause at 1, 2, and 3 years after treatment.
Time frame: 12 months, 24 months and 36 months visits
Recurrence-free survival
Compare recurrence-free survival after local excision complicated by intraoperative perforation versus uncomplicated cases.
Time frame: 12 months visit
Adherence to oncological follow-up recommendations
Evaluate adherence to oncological follow-up recommendations proposed in multidisciplinary tumor board (MTB) meetings and/or by the operator.
Time frame: 12 months visit
Oncological risk factors
Evaluate oncological risk factors for lymph node and/or metastatic recurrence following local excision of a superficial colorectal cancer.
Time frame: 12 months visit
Healthcare resource utilization.
Compare healthcare resource utilization.
Time frame: at 30 days, 3, 12, 24 and 36 months
New histo-prognostic risk factors
Investigate new histo-prognostic risk factors using molecular biology and proteomic profiling on submucosal dissection specimens.
Time frame: 12 months visit
Start is estimated for Oct 2026; primary completion for Dec 2030, 50 months later.
Of 461 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 132. This study's planned 50 months is below that.
Counting every sponsor, half of 562 studies reached it within 53 months; a quarter within 28 and three quarters within 103.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →